GSK
787 hedge funds and large institutions have $11.1B invested in GSK in 2018 Q2 according to their latest regulatory filings, with 66 funds opening new positions, 224 increasing their positions, 309 reducing their positions, and 50 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0.02% less ownership
Funds ownership: 4.45% → 4.43% (-0.02%)
7% less funds holding in top 10
Funds holding in top 10: 15 → 14 (-1)
28% less repeat investments, than reductions
Existing positions increased: 224 | Existing positions reduced: 309
Holders
787
Holding in Top 10
14
Calls
$145M
Puts
$80.5M
Top Buyers
| 1 | +$73.2M | |
| 2 | +$60.2M | |
| 3 | +$49M | |
| 4 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$45.7M |
| 5 |
Morgan Stanley
New York
|
+$23.9M |
Top Sellers
| 1 | -$58.6M | |
| 2 | -$51M | |
| 3 | -$35.7M | |
| 4 |
DM
Deerfield Management
New York
|
-$31.6M |
| 5 |
ORIO
Old Republic International (ORI)
Chicago,
Illinois
|
-$28.9M |